BPC-157 vs NAD+ (Nicotinamide Adenine Dinucleotide)
Updated July 28, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of BPC-157 and NAD+ (Nicotinamide Adenine Dinucleotide) (also searched as NAD+ (Nicotinamide Adenine Dinucleotide) vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
BPC-157 centers on healing, while NAD+ (Nicotinamide Adenine Dinucleotide) leans toward metabolic. On indexed research, NAD+ (Nicotinamide Adenine Dinucleotide) is ahead (BPC-157: 9 studies, Human evidence; NAD+ (Nicotinamide Adenine Dinucleotide): 22, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •BPC-157 is strongest for healing; NAD+ (Nicotinamide Adenine Dinucleotide) for metabolic.
- •Evidence: BPC-157 Human evidence (9 studies) vs NAD+ (Nicotinamide Adenine Dinucleotide) Human evidence (22).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Body Protection Compound-157 | Pentadecapeptide
Essential Cellular Coenzyme & Anti-Aging Therapy
BPC-157 vs NAD+ (Nicotinamide Adenine Dinucleotide): side-by-side
| Metric | BPC-157 | NAD+ (Nicotinamide Adenine Dinucleotide) |
|---|---|---|
| Class | Healing | Longevity |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 9 | 22 |
| Research level | Extensively Studied | Extensively Studied |
| Strongest effect | Healing & recovery | Metabolic & appetite |
| Healing & recovery | 4.0▲ | 4.0▲ |
| Muscle & body comp | 3.0▲ | 2.0 |
| Metabolic & appetite | 2.0 | 5.0▲ |
| Neuro & mood | 3.0▲ | 3.0▲ |
| Sleep & circadian | 1.0 | 2.0▲ |
| Inflammation & immune | 4.0▲ | 4.0▲ |
| Skin & aesthetics | 2.0▲ | 1.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | BPC-157 | NAD+ (Nicotinamide Adenine Dinucleotide) |
|---|---|---|
| Mechanism | Body-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling | Coenzyme in redox reactions |
| Route | Subcutaneous / oral (research use) | Intravenous infusion |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is BPC-157?
Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.
Full BPC-157 profile, mechanism & studies →What is NAD+ (Nicotinamide Adenine Dinucleotide)?
### Summary NAD+ (Nicotinamide adenine dinucleotide) is a crucial coenzyme involved in various metabolic processes, including energy production and cellular repair mechanisms. Recent research highlights its potential roles in protecting against oxidative stress and enhancing therapeutic efficacy in certain cancer treatments.
Full NAD+ (Nicotinamide Adenine Dinucleotide) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~4.0/5 |
| Muscle | BPC-157 | 3.0/5 effect signal |
| Metabolic | NAD+ (Nicotinamide Adenine Dinucleotide) | 5.0/5 effect signal |
| Neuro | Even | Both ~3.0/5 |
| Sleep | NAD+ (Nicotinamide Adenine Dinucleotide) | 2.0/5 effect signal |
| Inflammation | Even | Both ~4.0/5 |
| Skin | BPC-157 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack BPC-157 and NAD+ (Nicotinamide Adenine Dinucleotide)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
BPC-157 vs NAD+ (Nicotinamide Adenine Dinucleotide): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
BPC-157 has 9 approved studies indexed (Human evidence), and NAD+ (Nicotinamide Adenine Dinucleotide) has 22 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is BPC-157 or NAD+ (Nicotinamide Adenine Dinucleotide) better?
It depends on your goal. BPC-157 is strongest for healing; NAD+ (Nicotinamide Adenine Dinucleotide) for metabolic. NAD+ (Nicotinamide Adenine Dinucleotide) has more indexed studies (22). See the goal-by-goal breakdown above.
Is BPC-157 or NAD+ (Nicotinamide Adenine Dinucleotide) better for weight loss?
NAD+ (Nicotinamide Adenine Dinucleotide) shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is BPC-157 or NAD+ (Nicotinamide Adenine Dinucleotide) better for muscle?
BPC-157 leads on the muscle & body-composition axis (3.0/5).
Which has more research, BPC-157 or NAD+ (Nicotinamide Adenine Dinucleotide)?
BPC-157 has 9 approved studies indexed (Human evidence); NAD+ (Nicotinamide Adenine Dinucleotide) has 22 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack BPC-157 and NAD+ (Nicotinamide Adenine Dinucleotide)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of BPC-157 vs NAD+ (Nicotinamide Adenine Dinucleotide)?
BPC-157: no community-reported effects logged yet. NAD+ (Nicotinamide Adenine Dinucleotide): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is BPC-157 or NAD+ (Nicotinamide Adenine Dinucleotide) FDA-approved?
BPC-157 is a research-use compound and is not FDA-approved. NAD+ (Nicotinamide Adenine Dinucleotide) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is NAD+ (Nicotinamide Adenine Dinucleotide) better than BPC-157?
For metabolic, NAD+ (Nicotinamide Adenine Dinucleotide) has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
BPC-157 and NAD+ (Nicotinamide Adenine Dinucleotide) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 28, 2026.